Dyadic to Present at 2022 Jefferies Healthcare Conference
June 02, 2022 09:27 ET
|
Dyadic International, Inc.
JUPITER, Fla., June 02, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...
Dyadic to Present at H.C. Wainwright Global Investment Conference
May 20, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments
May 12, 2022 16:00 ET
|
Dyadic International, Inc.
New research, license, and collaboration agreement with a Global Food Ingredients Company using Dyadic’s proprietary biotechnologiesLicense agreement with Phibro/Abic Animal Health to develop and...
Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients
May 11, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”
May 09, 2022 08:30 ET
|
Dyadic International, Inc.
Toxicology data published in the international peer-reviewed scientific journal “Toxicologic Pathology” demonstrates excellent safety profile and lasting immunogenic response from Dyadic’s DYAI-100,...
Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
April 28, 2022 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 28, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform
April 13, 2022 08:52 ET
|
Dyadic International, Inc.
India’s Department of Biotechnology, Government of India to support scale up and production of cGMP batches of SARS-CoV-2 antigenFunding earmarked to support Phase 1 and 2 clinical trials of Epygen’s...
Dyadic International to Present at Upcoming Scientific Medical Meetings
April 04, 2022 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 04, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and...
Dyadic Reports 2021 Year End Results and Recent Company Progress
March 29, 2022 16:00 ET
|
Dyadic International, Inc.
New research, license and collaboration agreement with Janssen for the development and manufacture of therapeutic proteinsReceived NIIMBL coronavirus grant of $690,000 under the White House’s American...
Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022
March 15, 2022 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...